Lorenza Rimassa: Patient Advocate on Immunotherapy Choices in HCC and NSCLC at ESMO Asia 2024
Lorenza Rimassa, Associate Professor of Medical Oncology at HUNIMED, shared a post on X:
“Patient advocate sharing patient’s preferences, goals, and values (not necessarily in this order) about (but not only) subcutaneous vs iv immunotherapy in HCC and NSCLC at ESMO Asia24 in Singapore. ”
At ESMO Asia 2024 in Singapore, a patient advocate shared important insights regarding the preferences, goals, and values of patients with hepatocellular carcinoma (HCC) and non-small cell lung cancer (NSCLC). The discussion highlighted the critical role of patient-centered care when deciding between treatment options, such as subcutaneous versus intravenous (IV) immunotherapy.
By focusing on individual preferences and quality of life, the advocate emphasized how these factors influence treatment choices, ensuring that therapies align with the patient’s personal values and overall treatment goals.
ESMO Asia is an annual congress specifically focused on multidisciplinary oncology in the Asian region.
ESMO Asia 2024 features scientific sessions covering a wide range of topics related to oncology, including advances in cancer research, new treatment modalities, and discussions on the management of specific types of cancer.
Its educational sessions provides in-depth training and insights into specific aspects of oncology, ensuring that participants gain practical knowledge that they can apply in their daily practice.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023